Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology ...

From acid reflux to immune reactions, esophagitis has many causes—learn about its symptoms, types, and the latest treatments ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil ...

Physicians and patient advocates are sounding the alarm after the NIH abruptly withdrew a grant renewal application for the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR ...

Patients with eosinophilic esophagitis who had an Index of Severity score of 15 or higher responded less favorably to topical corticosteroids, with lower rates of histologic remission, less symptom ...

NEW evidence from a large meta-analysis of randomised controlled trials (RCTs) confirms that type 2 inflammatory biomarkers, specifically blood eosinophil count and fractional exhaled nitric oxide ...

CXCL9 levels in patients with COPD significantly correlated with KL-6, SP-A, blood eosinophil ratio, lactate dehydrogenase (LDH), and CRP levels, with correlation coefficients of 0.243, 0.381, 0.225, ...

A retrospective case series found that treatment with an interleukin (IL)-5 inhibitor reduced eosinophil levels and improved clinical outcomes in patients with drug reaction with eosinophilia and ...

The FDA is reviewing the BLA for mepolizumab, an interleukin-5 (IL-5) antagonist monoclonal antibody, as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD) with an ...